Manson Fok - Jan 13, 2023 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
Director
Signature
/s/ Staci Holquist, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Jan 13, 2023
Transactions value $
$7,500
Form type
4
Date filed
1/17/2023, 07:30 AM
Previous filing
Oct 12, 2022
Next filing
Apr 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $7.5K +40.3K +1.96% $0.19 2.1M Jan 13, 2023 Direct F1
holding ATNXQ Common Stock 679K Jan 13, 2023 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Common Stock 107K Jan 13, 2023 By Avalon Polytom (HK) Limited F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 80K Jan 13, 2023 Common Stock 80K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Jan 13, 2023 Common Stock 48K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 20K Jan 13, 2023 Common Stock 20K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 40K Jan 13, 2023 Common Stock 40K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Jan 13, 2023 Common Stock 48K $7.50 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Jan 13, 2023 Common Stock 48K $9.00 Direct
holding ATNXQ Stock Option (Right to Buy) 27K Jan 13, 2023 Common Stock 27K $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 54.9K Jan 13, 2023 Common Stock 54.9K $9.00 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Stock Option (Right to Buy) 15K Jan 13, 2023 Common Stock 15K $17.30 Direct
holding ATNXQ Stock Option (Right to Buy) 10K Jan 13, 2023 Common Stock 10K $13.17 Direct F5
holding ATNXQ Stock Option (Right to Buy) 10K Jan 13, 2023 Common Stock 10K $12.45 Direct F6
holding ATNXQ Stock Option (Right to Buy) 6.25K Jan 13, 2023 Common Stock 6.25K $3.80 Direct
holding ATNXQ Stock Option (Right to Buy) 12.5K Jan 13, 2023 Common Stock 12.5K $0.46 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F3 Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F4 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F5 This option vests in four equal annual installments beginning on February 28, 2020.
F6 This option vests in four equal annual installments beginning on June 5, 2021.
F7 This option vests on June 28, 2023.